Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $29
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $30 to $29.
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $30 to $29.